

Supplemental material

Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-hoc Analysis of the MECANO Trial

Manuela Yepes-Calderón^{1,§}, Camilo G. Sotomayor^{1,§,*}, Daniel Guldager Kring Rasmussen², Ryanne S. Hijmans¹, Charlotte A. te Velde-Keyzer¹, Marco van Londen¹, Marja van Dijk¹, Arjan Diepstra³, Stefan P. Berger¹, Morten Asser Karsdal², Frederike J. Bemelman⁴, Johan W. de Fijter⁵, Jesper Kers^{6,7,8}, Sandrine Florquin^{6,7}, Federica Genovese², Stephan J.L. Bakker¹, Jan-Stephan Sanders¹, Jacob van den Born¹

¹Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

²Nordic Bioscience A/S, Herlev, Denmark

³Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

⁴Department of Nephrology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

⁵Department of Nephrology, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands

⁶Amsterdam UMC, University of Amsterdam, Department of Pathology, Amsterdam Institute for Infection and Immunity (AII), Amsterdam Cardiovascular Sciences (ACS), Amsterdam, The Netherlands

⁷Leiden University Medical Center, Department of Pathology, Leiden Transplant Center, Leiden, The Netherlands

⁸Van 't Hoff Institute for Molecular Sciences (HIMS), University of Amsterdam, Amsterdam, The Netherlands

§ These authors contributed equally to this work

* Correspondence: c.g.sotomayor.campos@umcg.nl; Tel.: 0031 061 921 08 81

Received: date; Accepted: date; Published: date

1. Supplemental table of content

Table S1. Biomarkers and histological characteristics during follow-up on KTRs by primary kidney disease..... Page 3

Table S2. Biomarkers and histological characteristics during follow-up on KTRs by primary kidney disease assuming all patients with unknown cause would have had glomerulonephritis as primary kidney disease.....Page 4

Table S1. Biomarkers and histological characteristics during follow-up on KTR by primary kidney disease

Biomarkers and histological characteristics	Primary kidney disease			P
	Polycystic kidney disease	Glomerulonephritis	Hypertension	
<i>n</i>	24	16	15	
Biomarkers				
6-months				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^a	10 (4.7)	8.7 (2.3)	9.7 (2.5)	0.85
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	6.8 (5.0-24.1)	7.2 (3.5-16.3)	3.9 (2.9-7.5)	0.99
24-months				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^c	10.3 (5.1)	9.3 (4.9)	9.3 (2.0)	0.99
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	5.9 (4.3-29.2)	7.4 (4.5-14.9)	6.0 (3.3-21.0)	0.58
Delta₂₄₋₆				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^c	0.2 (5.9)	-0.77 (2.7)	-0.29 (2.1)	0.83
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	-0.6 (-2.1-4.8)	1.1 (-2.5-5.5)	0.2 (-1.0-3.1)	0.31
Histological analyses				
6-months				
IF/TA-score	1.0 (0.0-1.0)	1.0 (0.0-1.0)	1.0 (1.0-1.0)	0.51
PSR, %	13.0 (6.7)	13.9 (5.7)	11.9 (6.6)	0.92
ti-score, %	10.0 (5.0-16.0)	9.0 (3.0-18.8)	10.0 (5.0-20.0)	0.55
24-months				
IF/TA-score	1.0 (1.0-1.8)	1.0 (1.0-1.8)	1.0 (1.0-2.0)	0.83
PSR, %	16.2 (7.5)	16.5 (11.6)	17.3 (13.2)	0.27
ti-score, %	20.0 (10.0-30.0)	10.0 (8.5-43.8)	15.0 (8.0-60.0)	0.17
Delta₂₄₋₆				
IF/TA-score	0.5 (0.0-1.0)	0.5 (0.0-1.0)	0.0 (0.0-1.0)	0.92
PSR, %	3.17 (7.5)	2.6 (12.1)	5.5 (13.7)	0.25
ti-score, %	10 (0-20)	2.5 (-5.75-16.8)	5.0 (-2.0-30.0)	0.20

Data available in ^a73, ^b62, ^c36 patients. CsA, cyclosporine group; EVL, everolimus group; PRO-C6, released pro-peptide of collagen type VI (endotrophin); IF/TA, interstitial fibrosis/tubular atrophy; PSR, Picro Sirius Red; ti-score, total inflammation score.

Table S2. Biomarkers and histological characteristics during follow-up on KTR by primary kidney disease assuming all patients with unknown cause would have had glomerulonephritis as primary kidney disease.

Biomarkers and histological characteristics	Primary kidney disease			<i>P</i>
	Polycystic kidney disease	Glomerulonephritis	Hypertension	
<i>n</i>	24	32	15	
Biomarkers				
6-months				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^a	10 (4.7)	8.6 (3.4)	9.7 (2.5)	0.77
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	6.8 (5.0-24.1)	7.95 (4.86-19.07)	3.9 (2.9-7.5)	0.99
24-months				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^c	10.3 (5.1)	9.2 (5.1)	9.3 (2.0)	0.98
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	5.9 (4.3-29.2)	7.4 (4.0-17.5)	6.0 (3.3-21.0)	0.58
Delta₂₄₋₆				
<i>Plasma</i>				
PRO-C6 (ng/mL) ^c	0.2 (5.9)	1.07 (3.4)	-0.29 (2.1)	0.80
<i>Urine</i>				
PRO-C6 (ng/mg creat) ^b	-0.6 (-2.1-4.8)	1.2 (-2.7-14.9)	0.2 (-1.0-3.1)	0.31
Histological analyses				
6-months				
IF/TA-score	1.0 (0.0-1.0)	1.0 (0.0-1.0)	1.0 (1.0-1.0)	0.41
PSR, %	13.0 (6.7)	13.4 (6.0)	11.9 (6.6)	0.87
ti-score, %	10.0 (5.0-16.0)	10.0 (5.0-15.0)	10.0 (5.0-20.0)	0.55
24-months				
IF/TA-score	1.0 (1.0-1.8)	1.0 (1.0-2.0)	1.0 (1.0-2.0)	0.79
PSR, %	16.2 (7.5)	17.3 (9.8)	17.3 (13.2)	0.20
ti-score, %	20.0 (10.0-30.0)	11.5 (8.5-38.3)	15.0 (8.0-60.0)	0.19
Delta₂₄₋₆				
IF/TA-score	0.5 (0.0-1.0)	1.0 (0.0-1.0)	0.0 (0.0-1.0)	0.88
PSR, %	3.17 (7.5)	3.8 (11.5)	5.5 (13.7)	0.19
ti-score, %	10 (0-20)	5.0 (-1.5-21.5)	5.0 (-2.0-30.0)	0.20

Data available in ^a73, ^b62, ^c36 patients. CsA, cyclosporine group; EVL, everolimus group; PRO-C6, released pro-peptide of collagen type VI (endotrophin); IF/TA, interstitial fibrosis/tubular atrophy; PSR, Picro Sirius Red; ti-score, total inflammation score.